Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.40 |
| ▸ | ANPEP | P15144 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MME | P08473 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28134518 | 0.93 | SIGMAR1 (0.47) | ANPEPALDH1A1MEN1KMT2AMAPT | |
| Acetic Acid SCHEMBL28995037 | 0.92 | ANPEP (0.40) | ANPEPALDH1A1MEN1KMT2AMAPT | |
| Acetic Acid SCHEMBL29156189 | 0.83 | TSHR (0.38) | ANPEPALDH1A1MEN1KMT2ACYP1A2 | |
| Acetic Acid SCHEMBL29156192 | 0.81 | P2RY6 (0.36) | ANPEPALDH1A1MEN1KMT2ACYP1A2 | |
| Acetic Acid SCHEMBL8540399 | 0.81 | MEN1 (0.57) | ALDH1A1MEN1KMT2AMAPTSIGMAR1 | |
| Acetic Acid SCHEMBL27733277 | 0.81 | MEN1 (0.57) | ALDH1A1MEN1KMT2AMAPTSIGMAR1 | |
| Acetic Acid SCHEMBL29290494 | 0.81 | MEN1 (0.57) | ALDH1A1MEN1KMT2AMAPTSIGMAR1 | |
| Acetic Acid SCHEMBL28252800 | 0.81 | MEN1 (0.57) | ALDH1A1MEN1KMT2AMAPTSIGMAR1 | |
| Acetic Acid SCHEMBL6940060 | 0.79 | MEN1 (0.52) | ANPEPALDH1A1MEN1KMT2ASIGMAR1 | |
| Acetic Acid SCHEMBL29170764 | 0.79 | KMT2A (0.59) | ALDH1A1MEN1KMT2AMAPTSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113563471-B | Anti-AXL antibodies | 卑尔根生物股份公司 | 2025-01-28 | — | — | CN | disclosed |
| CN-113321732-B | Anti-AXL antibodies | 卑尔根生物股份公司 | 2024-12-17 | — | — | CN | disclosed |
| CN-112062853-B | Bispecific HER2 antibodies and methods of use | 豪夫迈·罗氏有限公司 | 2024-01-09 | — | — | CN | disclosed |
| CN-111629754-B | anti-CD 47 antibodies that do not cause significant hemagglutination | 南京传奇生物科技有限公司 | 2023-10-20 | — | — | CN | disclosed |
| CN-116333148-A | Site-specific glycoengineering of targeting modules | 建新公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-110461877-A | The anti-antibody combined treatment of IL-36R | BOEHRINGER INGELHEIM INT | 2019-11-15 | — | — | CN | disclosed |
| CN-108779182-A | Bispecific antibody and application thereof with constant region mutation | 麻省理工学院 | 2018-11-09 | — | — | CN | disclosed |
| CN-107614010-A | It is bound to the antibody drug conjugates (ADC) of FLT3 albumen | 艾更斯司股份有限公司 | 2018-01-19 | — | — | CN | disclosed |
| CN-107124870-A | Immunoconjugates comprising an anti-HER 2 antibody and a pyrrolobenzodiazepine | 基因泰克公司 | 2017-09-01 | — | — | CN | disclosed |
| CN-107001479-A | anti-HER 2 antibodies and immunoconjugates | 基因泰克公司 | 2017-08-01 | — | — | CN | disclosed |
| CN-105873615-A | Covalently linked helicar-anti-helicar antibody conjugates and uses thereof | 豪夫迈·罗氏有限公司 | 2016-08-17 | — | — | CN | disclosed |
| CN-105873616-A | Covalently linked polypeptide toxin-antibody conjugates | 豪夫迈·罗氏有限公司 | 2016-08-17 | — | — | CN | disclosed |
| CN-104540524-A | Immunoconjugates comprising anti-CD22 antibodies | GENENTECH INC | 2015-04-22 | — | — | CN | disclosed |
| CN-104428007-A | Immunoconjugates comprising anti-cd22 antibodies | GENENTECH INC | 2015-03-18 | — | — | CN | disclosed |
| CN-104125852-A | Fc-receptor based affinity chromatography | HOFFMANN LA ROCHE | 2014-10-29 | — | — | CN | disclosed |